Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.

Journal of Hematology & Oncology
Naomi GaliliAzra Raza

Abstract

Approximately 70% of all patients with myelodysplastic syndrome (MDS) present with lower-risk disease. Some of these patients will initially respond to treatment with growth factors to improve anemia but will eventually cease to respond, while others will be resistant to growth factor therapy. Eventually, all lower-risk MDS patients require multiple transfusions and long-term therapy. While some patients may respond briefly to hypomethylating agents or lenalidomide, the majority will not, and new therapeutic options are needed for these lower-risk patients. Our previous clinical trials with ezatiostat (ezatiostat hydrochloride, Telentra®, TLK199), a glutathione S-transferase P1-1 inhibitor in clinical development for the treatment of low- to intermediate-risk MDS, have shown significant clinical activity, including multilineage responses as well as durable red-blood-cell transfusion independence. It would be of significant clinical benefit to be able to identify patients most likely to respond to ezatiostat before therapy is initiated. We have previously shown that by using gene expression profiling and grouping by response, it is possible to construct a predictive score that indicates the likelihood that patients without delet...Continue Reading

References

May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanJames F Holland
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Mar 25, 2006·Nature Reviews. Cancer·Aurora Esquela-Kerscher, Frank J Slack
May 2, 2006·The Journal of Biological Chemistry·Alix GazelMiroslav Blumenberg
Oct 6, 2006·The New England Journal of Medicine·Alan ListUNKNOWN Myelodysplastic Syndrome-003 Study Investigators
Feb 27, 2008·The Journal of Experimental Medicine·Ryan M O'ConnellDavid Baltimore
Jan 17, 2009·Cancer Research·Christopher D ScharerCarlos S Moreno
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Anita WolferSridhar Ramaswamy
Nov 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yoon-Jae ChoScott L Pomeroy
Mar 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pablo TamayoJill P Mesirov

❮ Previous
Next ❯

Citations

Jul 12, 2013·Journal of Hematology & Oncology·Lohith BachegowdaAmit Verma
Mar 1, 2015·Expert Opinion on Investigational Drugs·Daruka Mahadevan, Gregory Ryan Sutton
Oct 20, 2012·Seminars in Hematology·Austin G Kulasekararaj, Ghulam J Mufti
Dec 3, 2014·Biochimica Et Biophysica Acta·Zhi-Wei YeKenneth D Tew
Sep 14, 2018·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Carmen Mariana Aanei, Lydia Campos Catafal
May 24, 2018·Cardiovascular & Hematological Disorders Drug Targets·Ota Fuchs
Nov 24, 2012·Nature Reviews. Cancer·Azra Raza, Naomi Galili

❮ Previous
Next ❯

Datasets Mentioned

BETA
SP600125

Methods Mentioned

BETA
MDS

Software Mentioned

Gene Set Enrichment Analysis ( ssGSEA )
ezatiostat

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.